NCT03934606

Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model

Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model: A Pilot Study of Patient Outcomes

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,488 (actual)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate an alternative clinical genetics cancer care delivery model, using non-genetic providers to introduce and order genetic testing. 250 prostate and 250 pancreatic patients will be recruiting. They will undergo genetic testing and complete study questionnaires. Results from this pilot study will be used to inform the strategies used by the Clinical Risk Evaluation Program (CREP) Genetic Counelors (CGS) and GI/GU physicians to deliver genetic testing and return genetic risk information to patients with prostate or pancreatic cancer.

Conditions

• Pancreas Cancer
• Prostate Cancer
• Hereditary Cancer
• Genetic Predisposition to Disease

Interventions

Type	Name	Description
BEHAVIORAL	Genetic testing for hereditary predisposition	Change in distress levels (HADS-Anxiety) from Baseline to Assessments #2 and #3, measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance

Timeline

• Start date: 2018-01-01
• Primary completion: 2025-01-31
• Completion: 2025-01-31
• First posted: 2019-05-02
• Last updated: 2025-04-10

Locations

1 site across 1 country: United States